Job | Kyverna Therapeutics Platform & Pipeline Opportunity CAR T-Cell Therapy Pipeline Clinical Trials and Expanded Access Patients Experience Stiff Person Syndrome Myasthenia Gravis Multiple Sclerosis Lupus Nephritis Systemic Sclerosis Inside Kyverna Leadership Mission & Values Education & Events Publications Videos Investors News Careers Contact --> ← Back Inspection Readiness Project Manager (Contract) Remote Project Management Temp Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible. Summary We are seeking a highly experienced Inspection Readiness Project Manager to drive enterprise-wide inspection readiness, remediation, and quality system execution across clinical programs. This individual will serve as the central orchestrator across Clinical Operations, Quality, Regulatory, and external partners to ensure continuous state of inspection readiness for global health authority inspections (e.g., FDA, EMA). This role requires deep expertise in GxP environments, strong clinical development knowledge, and a proven ability to drive complex, cross-functional initiatives under tight timelines. Title: Inspection Readiness Project Manager Location: Remote. West coast highly preferred Duration: 6+ months Hourly rate: $80-$100/hr
Responsibilities Lead and maintain a global inspection readiness processes, timelines, and activities Collaborate closely with Kyverna QA, Clin Ops, Safety, Biometrics and other functions as needed to develop, align and drive inspection readiness remediation activities. Partner with Inspection readiness taskforce to define and operationalize inspection readiness frameworks, playbooks, and governance models Establish inspection simulation strategies, including mock audits and risk assessments Own end-to-end remediation planning and execution following audits/inspections Track and manage inspection findings, risks, and commitments through centralized dashboards Escalate risks proactively and implement mitigation strategies Build and manage integrated, cross-functional project plans with clear milestones and dependencies Drive accountability across stakeholders to meet critical timelines and deliverables Develop resource plans to support inspection readiness and remediation activities Partner with Quality to develop, refine, and implement SOPs, work instructions, and procedural documentation Ensure processes are aligned with GCP (Good Clinical Practice) and broader GxP
requirements Influence without authority to drive execution across a matrixed organization
Qualifications Bachelor’s degree required; advanced degree (MS, PhD, MBA) preferred 10+ years in biotech/pharma with experience in inspection readiness and remediation programs is a must Strong exposure to GCP, GxP, and global inspections Deep understanding of clinical trial processes, quality systems, and regulatory expectations Expertise in audit/inspection processes preferred Exceptional program management skills (complex, global, cross-functional initiatives) Ability to drive execution under pressure and tight regulatory timelines Strong stakeholder management and executive communication skills Experience in cell and gene therapy or other complex modalities strongly preferred Background in building or scaling inspection readiness programs from scratch Familiarity with clinical trial systems (e.g., TMF platforms, QMS tools) Apply for this job Links Home Platform & Pipeline Patients Inside Kyverna Education & Events Investors Careers Contact About Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. FOLLOW US ON SOCIAL Privacy Policy (US) Privacy Policy (EU/UK) Designed by Elegant Themes | Powered by WordPress
Salary
$80 - $100
Location
Remote
Total raised
$322.0M
Last stage
Public
Investors
Jeffrey Greve
Co-Founder
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.